Spazmalgon solution for injection, 2 mL, No. 5 in ampoules
Composition
Active ingredients: metamizole sodium monohydrate, pitophenone hydrochloride, fenpiverinium bromide;
1 mL of solution for injection contains: 500 mg of metamizole sodium monohydrate; 2 mg of pitophenone hydrochloride; 0.02 mg of fenpiverinium bromide;
excipients: water for injection.
Dosage Form
Solution for injection.
Main physicochemical properties: a clear liquid, virtually free of particles.
Pharmacotherapeutic group
Antispasmodics in combination with analgesics.
ATC code A03D A02.
Pharmacological properties
Pharmacodynamics.
Spazmalgon® is a combination drug with pronounced antispasmodic and analgesic activity.
Metamizole has pronounced analgesic and antipyretic effects, combined with milder anti-inflammatory and antispasmodic activity. Its effects result in the inhibition of prostaglandin and endogenous algogen synthesis, an increase in the excitability threshold in the thalamus, and effects on the hypothalamus and the formation of endogenous pyrogens.
Fenpiverine has a moderately pronounced ganglion-blocking and anticholinergic effect. It inhibits the tone and motility of the smooth muscles of the stomach, intestines, biliary tract, and urinary tract.
Pitofenone hydrochloride has a papaverine-like effect with pronounced antispasmodic activity on smooth muscle.
Pharmacokinetics.
Absorption: When administered intramuscularly, it is rapidly absorbed. Metamizole has a systemic bioavailability of approximately 85%.
Distribution: Metamizole is 50–60% bound to plasma proteins. It crosses the blood-brain and placental barriers. The volume of distribution is approximately 0.7 L/kg.
Metabolism: Metamizole undergoes extensive biotransformation in the liver. Its major metabolite, 4-methylaminoantipyrine (MAA), is metabolized in the liver to form other metabolites, including 4-aminoantipyrine (AA), which is pharmacologically active. Peak plasma concentrations (for all metabolites combined) are reached approximately 30–90 minutes after administration.
Excretion: It is excreted by the kidneys in the form of metabolites, with only 3% of the administered metamizole excreted unchanged. The half-life is approximately 10 hours.
Patients with hepatic impairment: The half-life of the active metabolite MAA is approximately three times longer in patients with hepatic impairment. Treatment with lower doses of metamizole is recommended for such patients.
Patients with renal impairment: In patients with renal impairment, the excretion of certain metabolites is reduced. Treatment with lower doses of metamizole is recommended for such patients.
Indications
For short-term symptomatic treatment of pain associated with smooth muscle spasms of internal organs:
- gastric and intestinal colic;
- renal colic associated with kidney stones;
- spastic dyskinesia of the biliary tract;
- dysmenorrhea.
Contraindications
- Hypersensitivity to the active ingredients, to pyrazolone derivatives (including in patients with a history of agranulocytosis following previous use of similar medications), or to other nonsteroidal anti-inflammatory drugs (NSAIDs).
- Severe liver and kidney dysfunction.
- Acute hepatic porphyria.
- Glucose-6-phosphate dehydrogenase deficiency.
- Gastrointestinal obstruction and megacolon.
- Bone marrow dysfunction (e.g., following treatment with cytostatic agents).
- Diseases of the hematopoietic system (agranulocytosis, leukopenia, anemia of any etiology, including aplastic anemia, infectious neutropenia).
- Grade II and III prostate adenoma.
- Atonia of the gallbladder and urinary bladder.
- Suspected surgical pathology.
- Hypotensive states and hemodynamic instability.
- Collaptoid states.
- Tachyarrhythmia.
- Angle-closure glaucoma.
- Bronchial asthma.
Interactions with other medications and other types of interactions
Combining Spazmalgon® with other medications requires special caution due to its metamizole content, which is a liver enzyme inducer.
Alcohol should be avoided while taking this medication, as there is a risk of mutual potentiation of effects.
Coumarin anticoagulants. When used concomitantly, metamizole may reduce the activity of coumarin anticoagulants as a result of hepatic enzyme induction.
Chlorpromazine and other phenothiazine derivatives. When used concomitantly with metamizole, there is a risk of severe hypothermia.
Cyclosporine. Metamizole reduces plasma levels of cyclosporine when used concomitantly.
Chloramphenicol and other myelotoxic agents. When used concomitantly with metamizole, there is an increased risk of bone marrow suppression.
Enzyme inducers (barbiturates, glutethimide, phenylbutazone) may weaken the effect of metamizole.
Metamizole significantly increases the maximum plasma concentrations of chloroquine.
CNS depressants, when combined with metamizole, enhance its analgesic effect.
Tricyclic antidepressants (psychophorine, amitriptyline), oral contraceptives, analgesics, allopurinol, and alcohol slow down the metabolism of metamizole, potentiate its effect when used concomitantly, and increase its toxicity.
Concomitant use with other analgesics and NSAIDs increases the risk of hypersensitivity reactions and other adverse reactions.
Sedatives and tranquilizers enhance the analgesic effect of the drug.
When Spazmalgon® is used concomitantly with quinine-containing drugs, the anticholinergic effect may be potentiated.
Spazmalgon® can be combined with hyoscine butylbromide, furosemide, and glibenclamide.
Pyrazolone derivatives are known to interact with captopril, lithium, methotrexate, and triamterene, as well as to alter the efficacy of antihypertensive drugs and diuretics. The extent to which metamizole causes these interactions is unknown.
Since metamizole may reduce the effect of certain medications, Spazmalgon® should be used with caution in combination with the following drugs:
- bupropion—used to treat depression or as an aid to smoking cessation;
- efavirenz – used to treat HIV/AIDS;
- methadone – used to treat addiction to illicit substances (so-called opioids);
- valproate—used to treat epilepsy or bipolar disorder;
- tacrolimus – used to prevent organ rejection in transplant patients;
- sertraline – used to treat depression.
Special Considerations for Use
There is a risk of anaphylactic reactions when treating with Spazmalgon®. At the first signs of hypersensitivity, administration of the drug should be stopped immediately, and urgent measures should be taken to alleviate the condition (epinephrine, glucocorticoids, antihistamines).
The risk of hypersensitivity reactions (anaphylactoid reactions) when using metamizole is significantly increased in patients with:
- food or drug hypersensitivity or atopic diseases (hay fever);
- analgesic asthma syndrome or analgesic idiosyncrasy manifesting as urticaria or angioedema, especially when accompanied by rhinosinusitis and nasal polyps;
- chronic urticaria;
- idiosyncrasy to dyes (e.g., tartrazine) or preservatives (e.g., benzoates);
- alcohol intolerance. Such patients react to even minimal amounts of alcoholic beverages with symptoms such as sneezing, watery eyes, and severe visual disturbances. This type of alcohol intolerance may be a sign of undiagnosed analgesic asthma syndrome.
Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug-induced eosinophilia with systemic symptoms (DRESS syndrome)—which can be life-threatening or fatal—have been reported during treatment with metamizole. Patients should be informed of the signs and symptoms of skin reactions and monitored closely. If signs and symptoms indicative of these reactions appear, treatment with metamizole should be discontinued and under no circumstances resumed (see the “Contraindications” section).
Spazmalgon® contains the active ingredient metamizole, and treatment with this drug carries a small but life-threatening risk of shock and agranulocytosis. The development of agranulocytosis is not dose-dependent and cannot be predicted. It may occur after the first dose or after repeated use. Typical signs of agranulocytosis include fever, sore throat, pain when swallowing, and inflammation of the mucous membranes of the mouth, nose, pharynx, anorectal region, and genital area. In the event of a sudden deterioration in general condition and the appearance of signs of agranulocytosis, treatment with metamizole should be discontinued immediately, without waiting for laboratory confirmation.
The drug should be used with caution in patients with chronic alcoholism and in elderly patients, as this may lead to an increased incidence of adverse reactions, particularly involving the gastrointestinal tract.
Use the drug with caution in patients receiving concomitant cytostatic medications (only under medical supervision).
Do not use to relieve acute abdominal pain.
When treating patients with Spazmalgon® who have hematological disorders or a history of such disorders, a risk-benefit assessment must be performed, and hematological status must be monitored throughout treatment.
This medication should be used with caution in patients with impaired renal function or a history of kidney disease (pyelonephritis, glomerulonephritis).
In cases of kidney or liver disease, the dosing regimen should be individualized due to the potential adverse effects of metamizole on the kidneys and the prolonged half-life of metamizole metabolites in cases of impaired liver function.
The drug should be used with caution in patients with obstructive gastrointestinal disorders (achalasia, pyloroduodenal stenosis). Repeated use of Spazmalgon® in these cases may cause delayed emptying of gastrointestinal contents and intoxication.
The use of Spazmalgon® in patients with gastroesophageal reflux disease, intestinal atony, inflammatory bowel diseases—including nonspecific ulcerative colitis and Crohn’s disease— glaucoma, myasthenia gravis, or heart diseases (arrhythmias, ischemic heart disease, congestive heart failure) requires special caution and medical supervision.
The drug should be used with caution in patients who have had a myocardial infarction, those with severe arterial hypotension, and in the treatment of patients with systolic blood pressure below 100 mm Hg.
Metamizole, a component of Spazmalgon®, may cause hypotensive reactions. These reactions are dose-dependent and are more commonly observed with parenteral administration. The risk of such reactions increases in the following cases:
- in patients with pre-existing hypotension, fluid and electrolyte depletion or dehydration, unstable hemodynamics, or circulatory failure (for example, in patients with myocardial infarction or multiple trauma);
- in patients with elevated body temperature.
In such patients, the need for administration of the drug should be carefully assessed, and close monitoring should be performed. It may be necessary to take precautionary measures (e.g., stabilization of blood circulation) to reduce the risk of hypotension.
Spazmalgon® should be used only under close monitoring of hemodynamic parameters in patients in whom a decrease in blood pressure must be avoided at all costs, such as those with severe ischemic heart disease or significant cerebral vascular stenosis.
Hepatitis has been observed in patients treated with metamizole, with symptoms developing anywhere from a few days to several months after the start of treatment.
If a patient develops symptoms that may indicate liver damage, such as nausea or vomiting, fever, fatigue, loss of appetite, dark urine, pale stools, yellowing of the skin or whites of the eyes, itching, a rash, or pain in the upper abdomen, they must stop taking Spazmalgon® and consult a doctor. The doctor must evaluate the patient’s liver function.
Spazmalgon® should not be used if the patient has previously experienced liver damage during treatment with metamizole.
Spazmalgon® should be used only after a careful assessment of the benefit-risk ratio and with appropriate precautions in patients with impaired kidney or liver function.
Do not exceed the recommended doses of the medication.
Use during pregnancy or breastfeeding.
Pregnancy. Use of the drug during pregnancy is contraindicated due to a lack of clinical data.
Breastfeeding. Since metamizole metabolites are excreted in breast milk, the drug should not be prescribed during breastfeeding. If use of the drug cannot be avoided, breastfeeding should be discontinued for 48 hours following administration of the drug.
Effect on reaction time when operating motor vehicles or other machinery.
The active ingredient, fenpiverinium bromide, has a cholinergic-blocking effect and may cause dizziness and impaired accommodation. Metamizole may adversely affect attention and impair reaction time. Patients who drive or operate machinery should be warned about the drug’s potential side effects. Activities requiring increased attention should be discontinued until side effects subside.
Dosage and Administration
Spazmalgon®, solution for injection, is for intramuscular use only! Use only for short-term treatment!
The solution for injection should be administered under strict medical supervision due to the risk of anaphylactic shock in patients with hypersensitivity to metamizole or pyrazolone derivatives.
Adults and children 15 years of age and older.
Adults and children aged 15 years and older (weighing more than 53 kg) should receive an intramuscular injection of 2 to 5 mL of the solution for injection. If necessary, repeat the dose after 6–8 hours. The maximum daily dose should not exceed 6 mL of the injection solution (equivalent to 3 g of metamizole sodium). Duration of treatment: 2–3 days. Once a therapeutic effect is achieved, treatment may be switched to oral analgesics and antispasmodics. If no therapeutic effect is observed, discontinue treatment with this medication.
Patients aged 65 years and older.
A dose reduction is usually not necessary. In patients with age-related liver and kidney dysfunction, the dose should be reduced, as the half-life of metamizole metabolites may be prolonged.
Patients with renal impairment.
Metamizole is excreted in the urine as metabolites. In patients with mild to moderate renal impairment, it is recommended to use half the adult dose.
Patients with hepatic impairment.
In these patients, the half-life of the active metabolites of metamizole is prolonged. High doses should be avoided in patients with hepatic impairment. For short-term use, there is no need to reduce the dose.
There is insufficient experience with long-term use in patients with renal or hepatic impairment.
Children
Do not use this medication to treat children under 15 years of age.
Overdose
Symptoms: Symptoms of metamizole intoxication predominate, combined with anticholinergic manifestations. The most common manifestations include toxic-allergic syndrome, hematotoxicity, gastrointestinal disturbances, and neurological manifestations, including hypothermia, marked decrease in blood pressure, palpitations, shortness of breath, tinnitus, nausea, vomiting, gastralgia, weakness, oliguria, anuria, drowsiness, delirium, impaired consciousness, tachycardia, and convulsive syndrome; possible development of acute agranulocytosis, hemorrhagic syndrome, acute renal and hepatic failure, and respiratory muscle paralysis.
Treatment: Discontinue use of the drug and take measures to rapidly eliminate it from the body (forced diuresis, infusion of water-salt solutions, hemodialysis if necessary). Administer symptomatic treatment. There is no specific antidote.
Side Effects
The adverse reactions listed below are primarily caused by metamizole, which is a component of the drug.
Blood and lymphatic system disorders: leukopenia, agranulocytosis, thrombocytopenia, anemia (hemolytic anemia, aplastic anemia).
The risk of agranulocytosis cannot be predicted. Agranulocytosis may occur even in patients who have used metamizole in the past without experiencing similar adverse reactions.
Immune system disorders: anaphylactic shock, anaphylactic or anaphylactoid reactions, especially following parenteral administration. Such reactions may occur during administration of the drug or immediately after administration is discontinued, but may also appear several hours later. They usually occur within the first hour after injection. Milder reactions manifest as typical skin and mucous membrane reactions (such as itching, burning, redness, hives, swelling—localized or generalized), dyspnea, and, rarely, gastrointestinal complaints. Mild reactions may progress to more severe forms with generalized hives, severe angioedema (including laryngeal angioedema), severe bronchospasm, cardiac arrhythmias, and a drop in blood pressure (sometimes preceded by a rise in blood pressure).
For this reason, if any hypersensitivity skin reaction, symptoms of impaired renal function, or hematotoxic reactions occur, use of the drug should be discontinued immediately.
Asthma attack (in patients with analgesic-induced asthma), circulatory shock. Shock may be accompanied by cold sweats, dizziness, drowsiness, altered consciousness, pale skin, a feeling of tightness in the chest, shallow breathing or tachypnea, tachycardia, cold extremities, and a sharp drop in blood pressure. At the first signs of shock, treatment must be discontinued and appropriate emergency measures taken immediately.
Skin and subcutaneous tissue disorders: fixed drug eruption, maculopapular and other types of rashes, Lyell’s syndrome, angioedema, and decreased sweating. Severe skin reactions have been reported, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and (with unknown frequency) drug-induced eosinophilia with systemic symptoms (DRESS) have been reported with the use of metamizole (see the “Special Precautions for Use” section).
If any skin reaction occurs, metamizole should be discontinued immediately.
Nervous system: dizziness, headache.
Sensory system (vision): visual disturbances, accommodation disorders.
Cardiovascular system: palpitations, tachycardia, cardiac arrhythmia, cyanosis, hypotension, flushing. Hypotensive reactions may rarely occur during or after administration. They may or may not be accompanied by other symptoms of anaphylactoid or anaphylactic reactions. Rarely, such reactions may result from a sharp drop in blood pressure. Rapid intravenous administration increases the risk of hypotensive reactions.
A critical drop in blood pressure without other signs of hypersensitivity is dose-dependent and may manifest as hyperpyrexia.
Gastrointestinal: dry mouth, nausea, vomiting, abdominal pain and discomfort, constipation, exacerbation of gastritis and peptic ulcer disease, in rare cases, vomiting with blood and intestinal bleeding, ulcerations, and a burning sensation in the epigastric region.
Liver and biliary tract disorders: drug-induced liver injury, including acute hepatitis, jaundice, and elevated liver enzyme levels.
Urinary system: proteinuria, oliguria, anuria, polyuria, interstitial nephritis, red-colored urine, urinary retention, difficulty urinating, and impaired renal function.
Respiratory system: bronchospasm.
General disorders and administration site conditions: following parenteral administration—asthenia, pain at the injection site, and local reactions.
Shelf life
4 years.
Storage conditions
Keep out of reach of children.
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze.
Incompatibility
Do not administer this medication together with other medications in the same syringe.
Packaging
2 mL or 5 mL of solution for injection in an ampoule. 5 or 10 ampoules per blister pack. 1 blister pack per cardboard box.
Manufacturer
Sofarma JSC.
Address
16 Ilienske Shose St., Sofia, 1220, Bulgaria.
Similar products
Products from the same category










